VIVA-ASIA BLOOD AND MARROW TRANSPLANT CONSORTIUM AUTUMN SCHOOL 2024
5th October 2024 | 10:00AM - 12:50PM (GMT+8 SG Time)*
6th October 2024 | 10:15AM - 12:50PM (GMT+8 SG Time)*
Since 2017, the VABMT Consortium has organized a series of 'VABMT Schools' with the mission of bringing together international and regional experts to educate physicians on the latest advances and best practice in paediatric HSCT. We believe that the promises of HSCT and cellular therapy can bring about solutions even to the most challenging situations for children fighting cancers and hereditary diseases. We aim to empower emerging programs to set up and expand their HSCT service with support from centres of excellence, and at the same time, to drive innovations and nurture the next generation of leaders in paediatric HSCT.
ADMISSION DETAILS
Date: Saturday - Sunday, 5th - 6th October 2024
Virtual Meeting: Zoom
SYNOPSIS
Novel Triple Cellular Therapy with Tandem CAR-T, UCB, and TCRαβ-depleted Haploidentical HCT Completely Prevented Relapse in R/R Acute Leukemia by Prof Li Chun Fu
Relapse post hematopoietic cell transplant (HCT) still remains a major challenge in patients with relapsed/refractory (R/R) leukemia. Chimeric antigen receptor modified T cell (CAR-T) reducing leukemia burden and unrelated cord blood (UCB) having better anti-tumor effect than adult lymphocytes have well been recognized. It has also been proven, meanwhile, that antileukemia capacity based on NK allo-reactivity is potent in TCRab-depleted haploidentical HCT (TDH) because of high dose of NK cell infusion and reduced use of anti-GVHD medicines. Thus, we hypothesized that integration of multipronged approach including CAR-T, T/NK alloreactivity of UCB, and haplo-NK alloreactivity of TDH can synergistically eradicate leukemia cells by multiple cellular mechanisms in peri-graft period to prevent relapse. Hence, we developed a novel CAR-T-UCB-TDH protocol.
Immune Reconstitution post-HSCT for Inborn Errors of Immunity by Prof Andrew Gennery
- Over 450 inborn errors of immunity are currently reported. For many of these, the genetic defect is in the haematopoietic stem cell, and the disease amenable to correction by replacement of the defective stem cell by those from a healthy donor (which in some cases can be a carrier of the disease). Probably for all such procedures, best results are obtained in a pre-transplant cytoreductive conditioning regimen is applied. Full donor chimerism is not always achieved. Depending on the disease being treated, this may not be important, and understanding the disease, helps determine management of this complication. This presentation will detail approaches to conditioning, and management of donor chimerism states in different inborn errors of immunity.
PROGRAMME
WATCH IT AGAIN!
SPEAKERS
Prof Li Chun Fu
President of Nanfang-Chunfu Children's Institute of Hematology & Oncology
Director of Gaobo Medical (Hematology) Guangdong Research Center and Southern Chunfu (Children’s) Hematology Institute
China
Prof Godfrey Chan
Honorary Professor
Department of Paediatrics and Adolescent Medicine
School of Clinical Medicine, The University of Hong Kong
Consultant Paediatric Haematologist Oncologist
Hong Kong Sanatorium and Hospital
Hong Kong SAR
Prof Andrew Gennery
Sir James Spence Professor of Child Health and
Professor and Honorary Consultant in Paediatric Immunology + HSCT
Translational and Clinical Research Institute
Newcastle University
Great North Children's Hospital
Newcastle upon Tyne, UK
MODERATOR
Dr Pamela Lee
Clinical Associate Professor Department of Paediatrics and Adolescent Medicine
LKS Faculty of Medicine, The University of Hong Kong
Honorary Consultant, Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital; Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital
Department of Pediatrics, HKU-Shenzhen Hospital
Prof Hany Ariffin
Head and Senior Consultant Paediatric Haematology-Oncology and Blood & Marrow Transplantation Unit
University of Malaya Medical Centre
Malaysia